Previous 10 | Next 10 |
Puma Biotechnology ( PBYI ) has been a very volatile biotech stock in the last several years: Data by YCharts Last year, we published two articles about Puma with expected growth in the company's stock, Puma Biotechnology: Risky Investment and Puma Biotechnology: Increasing Our Ex...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in ...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. The presentation entitled, “Eff...
On May 9 after the market closed, Puma Biotechnology (NASDAQ: PBYI ) reported 1Q19 results . Nerlynx net sales came in much lower than expected and showed a sequential decline of 25%, causing management to lower full-year net sales guidance from $268M to $230M. The stock sold off heavily the ...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m. EDT on Thursday, June 6, at the Jefferies 2019 Global Healthcare Confe...
Puma Biotechnology ( PBYI ) reported very soft first quarter results as many readers asked me to review the situation in the wake of the latest news. Early March the company reported 2018 results as the final quarter of the year was strong and prompted a 40% short squeeze with shares rising ...
Results from a Phase 3 clinical trial, NALA , evaluating Puma Biotechnology's ( PBYI +3.2% ) Nerlynx (neratinib) + Roche chemo agent Xeloda (capecitabine) (N + C) compared to Novartis' ( NVS +1.6% ) Tykerb (lapatinib) + Xeloda (L + C) showed a treatment advantage. More news on...
Puma Biotechnology, Inc. (PBYI) Q1 2019 Results Earnings Conference Call May 09, 2019 04:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - President & Chief Executive Officer Steve Lo - Chief Commercial Officer Maximo Nougues - Chief Finan...
PBYI stock is the biggest loser in the biotech sector after Puma Biotechnology Inc. (NASDAQ:PBYI) reported disappointing revenue for its only commercial product, Nerlynx. Nevertheless, the company posted improved loss and revenue for the fiscal first quarter. Nerlynx’s Revenu...
Gainers: Charles & Colvard (NASDAQ: CTHR ) +34% . Buckeye Partners (NYSE: BPL ) +28% . Cardlytics (NASDAQ: CDLX ) +26% . G1 Therapeutics (NASDAQ: GTHX ) +24% . Westport Fuel Systems (NASDAQ: WPRT ) +21% . Cool Holdings (NASDAQ: AWSM ) +22% . Guardant Health (NASDAQ: GH ) +...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...